PMID- 11780206
OWN - NLM
STAT- MEDLINE
DCOM- 20020213
LR  - 20071115
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 114
IP  - 2
DP  - 2001 Feb
TI  - Autologous peripheral blood stem cell transplantation in the patients with 
      hematologic malignancies and solid tumors.
PG  - 196-9
AB  - OBJECTIVE: To evaluate the long-term therapeutic effects of autologous peripheral 
      blood stem cell transplantation (auto-PBSCT) on the treatment of hematological 
      and solid tumors. METHODS: Fifty-one patients were recruited in this auto-PBSCT 
      study, in which several potentially important parameters were studied including 
      the optimal time for stem cell collection, the dose of stem cell reinfusion, the 
      time of hematopoietic reconstitution, the disease free survival (DFS) and overall 
      survival (OS), complications related to transplantation, and maintenance 
      chemotherapy after auto-PBSCT. RESULTS: After APBSCT, 3-year and 5-year survival 
      rates of NHL were 83.3%; those of AML were 74.7%; those of MM were 37.9% and 19%; 
      those of ALL were 40% and 0% respectively. Hematopoietic reconstitution was 
      greatly promoted by granulocyte colony stimulating factor (G-CSF). The mean time 
      for patients' neutrophil to recover up to > 0.5 x 10(9)/L after APBSCT was 11.14 
      days in the group of the patients receiving G-CSF in contrast to 17.6 days in the 
      group receiving no G-CSF. The most common complications of transplantation were 
      fever, liver dysfunction and hypokalaemia, which were curable. No death was due 
      to transplantation related complications. CONCLUSION: Comparing with conventional 
      chemotherapy, our study suggests that auto-PBSCT is a very important therapeutic 
      option that can significantly improve the prognosis in the patients with 
      hematological and solid tumors, especially in the patients with AML and NHL.
FAU - Ke, X
AU  - Ke X
AD  - Hematology Department, Third Hospital, Peking University School of Medicine, 
      Beijing 100083, China.
FAU - Yang, Y
AU  - Yang Y
FAU - Zhao, X
AU  - Zhao X
FAU - Wang, L
AU  - Wang L
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Breast Neoplasms/mortality/pathology/therapy
MH  - Child
MH  - Female
MH  - Follow-Up Studies
MH  - Granulocyte Colony-Stimulating Factor/pharmacology
MH  - Hematologic Neoplasms/mortality/pathology/*therapy
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Hematopoietic Stem Cells/cytology/drug effects
MH  - Humans
MH  - Leukemia, Myeloid, Acute/mortality/pathology/therapy
MH  - Lymphoma, Non-Hodgkin/mortality/pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/mortality/pathology/therapy
MH  - Neoplasms/mortality/pathology/*therapy
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality/pathology/therapy
MH  - Survival Analysis
MH  - Survival Rate
MH  - Transplantation, Autologous
MH  - Treatment Outcome
EDAT- 2002/01/10 10:00
MHDA- 2002/02/14 10:01
CRDT- 2002/01/10 10:00
PHST- 2002/01/10 10:00 [pubmed]
PHST- 2002/02/14 10:01 [medline]
PHST- 2002/01/10 10:00 [entrez]
PST - ppublish
SO  - Chin Med J (Engl). 2001 Feb;114(2):196-9.